Department of Cell Biology, Ludwig Center at Harvard, Harvard Medical School, Boston, MA 02115, USA.
Department of Cell Biology, Ludwig Center at Harvard, Harvard Medical School, Boston, MA 02115, USA; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02115, USA.
Cancer Cell. 2018 Jun 11;33(6):985-1003.e7. doi: 10.1016/j.ccell.2018.05.001. Epub 2018 May 24.
Cancer cell survival is dependent on oxidative-stress defenses against reactive oxygen species (ROS) that accumulate during tumorigenesis. Here, we show a non-canonical oxidative-stress defense mechanism through TRPA1, a neuronal redox-sensing Ca-influx channel. In TRPA1-enriched breast and lung cancer spheroids, TRPA1 is critical for survival of inner cells that exhibit ROS accumulation. Moreover, TRPA1 promotes resistance to ROS-producing chemotherapies, and TRPA1 inhibition suppresses xenograft tumor growth and enhances chemosensitivity. TRPA1 does not affect redox status but upregulates Ca-dependent anti-apoptotic pathways. NRF2, an oxidant-defense transcription factor, directly controls TRPA1 expression, thus providing an orthogonal mechanism for protection against oxidative stress together with canonical ROS-neutralizing mechanisms. These findings reveal an oxidative-stress defense program involving TRPA1 that could be exploited for targeted cancer therapies.
癌细胞的存活依赖于氧化应激防御机制,以对抗肿瘤发生过程中积累的活性氧(ROS)。在这里,我们展示了一种非经典的氧化应激防御机制,涉及到 TRPA1,一种神经元氧化还原感应 Ca 内流通道。在富含 TRPA1 的乳腺癌和肺癌球体中,TRPA1 对于表现出 ROS 积累的内部细胞的存活至关重要。此外,TRPA1 促进了对产生 ROS 的化疗药物的耐药性,而 TRPA1 抑制则抑制了异种移植肿瘤的生长并增强了化疗敏感性。TRPA1 不会影响氧化还原状态,但会上调 Ca 依赖性抗凋亡途径。NRF2,一种抗氧化防御转录因子,直接控制 TRPA1 的表达,因此为对抗氧化应激提供了一种与经典 ROS 中和机制正交的机制。这些发现揭示了一种涉及 TRPA1 的氧化应激防御程序,可用于靶向癌症治疗。